ACXP - Wutah pendapatan taun lumaku acurxpharma.com

Tandha merek Acurx Pharmaceuticals Inc. (ACXP)

Acurx Pharmaceuticals (ACXP) is developing advanced gastrointestinal antibiotics that preserve beneficial microflora and is implementing software robots for clinical data analysis. However, a narrow focus on combating C. difficile and competition from generics create risks. The relative sales growth over a 12-month period compared to last year confirms these trends, and the value of 0.00 reflects the balance of the current revenue metric.

Wutah dodolan YoY (TTM): Acurx Pharmaceuticals Inc. (ACXP) kanggo 11.02.2024 - 18.11.2026

Acurx Pharmaceuticals Inc. - rincian analitis lan metrik utama (ACXP)

- rega saham lan target rega konsensus:
Analisis kabeh metrik perusahaan:Acurx Pharmaceuticals Inc.
Produk seri Acurx Pharmaceuticals, Inc.

To build a high-quality portfolio, I use this indicator as a tool to measure the rolling year revenue expansion rate on a daily basis. This model eliminates quarterly gaps, allowing for a comparison of current revenues with the same period last year, which is critical for Acurx Pharmaceuticals (ACXP), as its clinical trial costs are growing faster than operating revenue, reflecting a lack of scaling leverage in the annual dynamics of sales proceeds over four quarters.